Table 3.
Comparison of the sensing performance of different electrochemical immunosensors for CA19-9
| Sensing interface | Linear range (U/mL) | Limit of detection (U/mL) | Clinical samples detection | Refernces |
|---|---|---|---|---|
| Anti-CA19-9/AuNPs/poly(thionine)-SDS nanocomposites | 5–400 | 0.45 | Not mentioned | 39 |
| Cation-exchange-labeling anti-CA19-9 and methylene blue | 5–100 | 1.6 | 4 samples | 48 |
| Electrochemical microfluidic chip with K3[Fe(CN)6]/K4[Fe(CN)6] | 10.75–172 | 10.75 | 150 samples | 49 |
| HRP-Ab1/TiO2 collosol–gel matrix | 3–20 | 2.68 | 9 samples | 50 |
| ZnO quantum dot-labeled anti-CA19-9 | 0.1–180 | 0.04 | Not mentioned | 51 |
| Anti-CA19-9/3D-ordered macroporous magnetic Au film | 0.05–15.65 | 0.01 | 4 samples | 52 |
| Anti-CA19-9/AuNPs/poly(thionine)-SDS nanocomposites | 6.5–520.0 | 0.26 | 30 samples containing normal serum and pancreatic cancer serum | This work |
Abbreviations: CA19-9, carbohydrate antigen 19-9; HRP, horseradish peroxidase; SDS, sodium dodecyl sulfonate.